Gary A. Lyons, Director at Travere Therapeutics, Inc. (TVTX), sold 8,000 shares at $41.07 ($329K) on 2026-04-14, disclosed to the SEC on 2026-04-16.
Scheduled sale ($329k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| TVTX | SELL | 2024-10-04 | $1.2M | — | Filing → |
| NBIX | SELL | 2024-08-15 | $3.5M | — | Filing → |
| NBIX | SELL | 2024-07-18 | $279K | — | Filing → |